Summer Street Says Fast Track Unlikely for Sarepta's Eteplirsen

Loading...
Loading...
Summer Street released a note to clients Tuesday morning arguing Sarepta's
SRPT
eteplirsen drug is unlikely to be approved under Subpart H accelerated approval given its 12-patient Phase 2 trial. According to the firm, an FDA source recently cited a comparison of eteplirsen's dystrophin production to Vertex's
VRTX
cystic fibrosis drug Kalydeco. Vertex's drug showed early dramatic sweat chloride reductions but still needed 2-48 week Phase 3 studies. Sarepta shares are up 1.4 percent to $30.49 in mid-day action Tuesday.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst Ratings
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...